Oyekoya (Koya) Ayonrinde
316 posts
@GutLiver
Gastroenterologist/ Hepatologist, Clinician Researcher. MD PhD FRACP FAASLD FASGE. #NAFLD #MAFLD #MASLD, Liver Fibrosis #Cardiometabolic, #DOHaD, #UGIB, #Polyps
Hepatic Steatosis and High-Risk Coronary Plaque: A Systematic Review | JACC: Cardiovascular Imaging jacc.org/doi/10.1016/j.…
Here is another very interesting poster from this week's American Diabetes Association conference. "The leading cause of death in patients with steatotic liver disease (SLD) is CVD." "As SLD is frequently associated with metabolic disorders such as type 2 diabetes (DM), the concept of MASLD has been proposed. MASLD can be classified according to the type of associated metabolic dysfunction. Among MASLD subtypes, MASLD with DM (DM-MASLD) was shown to have a major impact on the development of CVD. However, the presence of SLD and status of concomitant metabolic abnormalities change over time. Since it is unclear how the incidence of CVD changes when DM-MASLD transitions, this study aimed to clarify this issue." "Changes in incidence of CVD due to changes in DM and MASLD status are shown in Figure 1. Remission in DM and MASLD each significantly reduced the incidence of CVD. Remission of hepatic steatosis in DM-MASLD patients was comparable to remission of DM in preventing new onset of CVD." Poster: 1278-P - Changes in Cardiovascular Disease (CVD) Incidence Due to Remission of Diabetes and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Poster lead author: Yasuhiro Matsubayashi. @EASLnews @AASLDtweets @CASLupdates @EuropeLiver @GlobalLiver @scottisaacsmd @ISGLOBALorg
@FattyLiverA @ISGLOBALorg @AleksanderKrag @FrancqueSven @schattenbergJ @Statofish @EASLnews @AASLDtweets @EuropeLiver @GlobalLiver Liver health is also #publichealth... Great to see that on the #EASLcongress programme. It is also #GlobalHealth - and the #HealthyLiversHealthyLives coalition seeks to make liver disease part of the #GlobalGoals.
